This review covers how peptides can spontaneously organize into nanoscale structures that deliver drugs to specific disease sites and release them on cue.
Carries both hydrophobic and hydrophilic drugsSelf-assembled peptide nanostructures can load drugs regardless of water solubility, overcoming a major limitation of many delivery systems
What the researchers found
Self-assembled peptide nanostructures offer several key advantages as drug delivery vehicles: chemical diversity that allows customization, biocompatibility with human tissue, high loading capacity for both hydrophobic and hydrophilic drugs, and the ability to target specific molecular recognition sites on cells.
By incorporating novel peptide motifs, researchers can make these structures stimuli-responsive — meaning they remain stable during transport through the body but release their drug cargo when they encounter specific conditions (like the acidic environment of a tumor or certain enzymes at an infection site).
Why it matters
Getting drugs to the right place in the body at the right time remains one of medicine's biggest challenges. Self-assembled peptide nanostructures represent a promising solution because they're made from natural amino acid building blocks (so the body tolerates them well), can be designed to seek out disease targets, and can be triggered to release drugs only where needed — potentially reducing side effects while improving treatment effectiveness.
How the study worked
This is a comprehensive review article that surveyed recent published studies on self-assembled peptide nanostructures, focusing specifically on their design for targeted and stimuli-responsive drug delivery applications.
What this study cannot tell us
As a review article, this work summarizes existing research rather than presenting new experimental data. The review was published in 2016, so it does not cover developments from the past decade. Most studies reviewed were preclinical, and clinical translation of self-assembled peptide delivery systems remains limited.
How to read the evidence
This is a review article synthesizing existing preclinical research. It provides a comprehensive overview of the field but does not present original experimental data or clinical evidence.
When this study was published
Published in 2016, this review provides foundational context for the field. The core principles remain relevant, but significant advances in peptide nanotechnology have occurred since publication.
The bigger picture
This review maps the landscape of peptide-based nanotechnology for drug delivery as of 2016. The field has continued to grow since, with peptide nanostructures now being explored for cancer therapy, antibiotic delivery, vaccine platforms, and regenerative medicine. The principles outlined here — self-assembly, targeting, and triggered release — remain foundational to current peptide drug delivery research.
Questions still open
- Which self-assembled peptide nanostructure designs have advanced closest to clinical trials since this review?
- How do peptide-based delivery systems compare to lipid nanoparticles (like those used in mRNA vaccines) in terms of clinical viability?
- Can self-assembled peptide systems be designed for oral drug delivery, or are they primarily suited for injection?
Common questions
What does 'self-assembly' mean in the context of peptides?
Why are peptide nanostructures considered 'smart' drug carriers?
Read the original research
Self-assembled peptide-based nanostructures: Smart nanomaterials toward targeted drug delivery.
Nano today, 11(1), 41-60
Citation
Habibi, Neda; Kamaly, Nazila; Memic, Adnan; Shafiee, Hadi. (2016). Self-assembled peptide-based nanostructures: Smart nanomaterials toward targeted drug delivery.. Nano today, 11(1), 41-60.